Tibetan Medicine (Sowa Rigpa)

Origins and the Four Tantras

A 2020 dataset paper by Tibetan medicine specialists describes Sowa Rigpa as a tradition that emerged between the seventh and twelfth centuries CE and spread most significantly in the thirteenth and seventeenth centuries, drawing on Indian, Chinese, Persian and Central Asian medical knowledge. The same paper calls the Four Medical Treatises (rGyud bzhi, often rendered Four Tantras) the seminal work of the canon and credits it to Yutok Yönten Gönpo, placed in the twelfth century. Dating and authorship are also discussed in specialist literature that the sources opened for this page do not settle.

Medicine and religious authority in early modern Tibet

A 2018 review of Janet Gyatso's intellectual history of early modern Tibetan medicine says that textual foundations were established in the twelfth century and that by the seventeenth century Tibetan medical authors and artists were treating medicine as a field of inquiry separate from religion. The reviewer adds that the regent Desi Sangyé Gyatso, who advanced that independence, ultimately favored authority based on Buddhist revelation over medical knowledge.

A second review of the same book describes a sixteenth-century scholar, Zurkharwa Lodro Gyelpo, who argued that the Four Treatises were of Tibetan rather than Indian provenance, which challenged their standing as the word of the Buddha. It reports that the regent answered with a sharp critique and halted publication of that scholar's work. Both accounts are reviews of the book, not the book itself.

Mongolia and exile

Anthropologist Stephan Kloos writes that Tibetan medicine was Mongolia's sole professional health resource from the seventeenth century, institutionalized with the Gelugpa monastic order, and that more than 100 Tibetan medical schools were founded in Inner and Outer Mongolia between 1662 and 1937. He describes pressure on lama doctors under communism, including arrests in 1933-1934, and argues that the tradition was reassembled in several places rather than simply interrupted.

After 1959 the Men-Tsee-Khang was re-established in Dharamsala, India. Kloos gives 1961 as the official date, while its founder cited 1965. The institute first aimed to preserve Tibetan culture and then to care for Tibetan refugees. By March 2006 it had 48 branch clinics in India and Nepal and 376 staff, including 111 physicians.

Names and regional terms

Kloos explains that Sowa Rigpa is the Tibetan term for 'science of healing' and is used by scholars for the family of Tibetan, Mongolian and Himalayan medical traditions based on one corpus of classical Tibetan texts and the ethics and epistemology of Tibetan Buddhism. Until at least the mid-twentieth century Mongolians called what is now termed Mongolian medicine 'tuvd emneleg' (Tibetan medicine) or 'lameen emneleg' (lama medicine). In Russia it is called Tibetan, not Mongolian, medicine.

A physician is called an amchi in Kloos's account of Tibetan clinics in India. The UNESCO text on Lum bathing names a manpa (physician), a lum jorkhan (pharmacist) and a manyok (assistant).

The three-part framework

A 2024 paper from Bhutan states that Sowa Rigpa holds the body to consist of three primary elements, rLung (air), mKhris-pa (bile) and Bad-kan (phlegm), and that health is a state of harmonious balance among them. The UNESCO description of Lum bathing names the same three as Lung, Tripa and Pekan, calls them three dynamics and places them within a view based on five elements. Spellings and English glosses differ across sources. The scheme is also called nyes pa in specialist writing, a term the opened sources do not define.

Texts and materia medica

The dataset paper names a seventeenth-century commentary on materia medica, the Stainless Crystal Rosary by Deumar Tendzin Püntsok (born 1672), and a modern reference, Gawé Dorjé's Stainless Crystal Mirror of Materia Medica, which it calls the most important reference for traditional identification across Tibetan medical institutions. Gawé Dorjé's system lists over 1,430 medicinal substances in eight divisions, and the paper's dataset covers about 690 commonly used botanical specimens with confirmed Latin names.

Pulse and urine examination

Geoffrey Samuel identifies pulse and urine examination as distinctive diagnostic techniques of Sowa Rigpa and says they raise questions about how subjective and objective dimensions of healing relate. The Bhutan paper calls them the primary diagnostic techniques. It describes urine assessed for nine features at three temperature stages (body temperature, lukewarm and cold), with sediment position said to indicate where disease lies in the body. The authors say heating of urine was introduced by Sangay Gyatso (1652-1705).

That paper tested a practical question, not diagnostic accuracy. At three Bhutanese hospitals between July 2021 and January 2022, 91 urine specimens (35 from men, 56 from women) were assessed at the physiological state and again after artificial heating. Most features did not differ significantly; two color categories did (p = 0.023 and p = 0.015). It was an observational study with no comparison against a reference diagnosis.

Medicines, bathing and institutions

A University of Vienna research project on Tibetan precious pills says they include pre-processed precious and semi-precious stones and metals, and that formulas contain between 25 and 150 herbal, animal, metallic and mineral ingredients. The UNESCO text describes Lum as bathing in natural hot springs, herbal water or steam, and says it has been incorporated into the curricula of modern medical colleges. Kloos reported that the Men-Tsee-Khang research department mainly conducted quality control and no clinical trials during his 2005-2009 fieldwork.

What the system is used for

The UNESCO text says Lum bathing aims to adjust the balance of body and mind, maintain health and treat illness. Tibetan medicine studies published in the West, according to a 2013 systematic review, addressed peripheral arterial occlusive disease, chronic infections, hepatitis B, diabetes, arthritis, constipation, cancer and multiple sclerosis. A Padma 28 overview by authors including an employee of its manufacturer says the formula has been registered in Switzerland as a drug for symptoms of circulatory disorders.

Researchers of Chinese traditional medicine report that five Tibetan patent medicines made mainly from precious materials such as gold, pearls and agate are widely used in China for ischemic stroke. These are uses described by practitioners and authors, and their evidence is addressed separately below.

How practitioners account for efficacy

In Kloos's interviews, Tibetan physicians in exile described medical knowledge as arising from ye shes, a power of mind gained through ethical discipline, meditation and an altruistic motivation. Some also saw science as a way to demonstrate the efficacy of Tibetan drugs to a global audience. Sienna Craig's ethnography asks what it means to say that Tibetan medicine 'works', following it through Nepal, China and global markets.

Overview of clinical studies

Reuter and colleagues searched seven databases to the end of 2010 and included 40 studies from 39 publications, among them 15 randomized controlled trials, out of 1,383 records screened. Padma 28 products made up about 70 percent of the literature. Mean Jadad score for the trials was 3.40, but only one case study and one trial met health technology assessment criteria. Results were too varied for meta-analysis, and the review excluded Russian, Tibetan and Chinese publications. The authors called the research available in the West scarce.

Padma 28 and intermittent claudication

The 2016 Cochrane update included five placebo-controlled trials with 365 participants and at least 16 weeks of follow-up; no new trials were found. Pooling two studies (193 participants) gave a mean difference of 95.97 m in maximum walking distance favoring Padma 28 (95% CI 79.07 to 112.88), rated very low quality. Ankle brachial index did not change, no quality-of-life data were reported, and the reviewers noted publication bias and withdrawals linked to the outcome. They concluded the evidence was insufficient for routine management.

A separate overview of 29 trials and 3 retrospective case series, written by authors with a manufacturer affiliation, found the highest level of evidence in intermittent claudication (11 trials) and called for further randomized trials. It does not replace the independent Cochrane appraisal.

Tibetan patent medicines for ischemic stroke

A 2023 meta-analysis pooled 17 randomized trials (1,603 patients) of five oral Tibetan patent medicines, searched to December 2022. Clinical effective rate favored the medicines (RR 1.23, 95% CI 1.17 to 1.29), as did neurological impairment score and activities of daily living. Certainty was rated low to very low by GRADE. Adverse events, reported in four trials, did not differ between groups. The authors called for higher-quality trials and drew no firm conclusion on blood indices or adverse events.

Gaps in the evidence

The sources reviewed for this page include no trial of the diagnostic accuracy of pulse or urine examination, no controlled trial of Lum bathing and no controlled trial of mercury-containing preparations. Evidence on a formula such as Padma 28 or on the stroke medicines does not extend to the whole system or to other formulas.

Industry and state policy

Kloos and colleagues, drawing on ethnographic research in China, India, Mongolia and Bhutan between 2014 and 2019, estimated the Sowa Rigpa pharmaceutical industry at 677.5 million US dollars in 2017, a tenfold rise since 2000. China accounted for 97.74 percent, India 1.62, Mongolia 0.59 and Bhutan 0.05. They concluded that state economic and health policy shaped industrial development and said their figures could not claim to be complete.

Community practice in India

A review of the edited volume Healing at the Periphery describes ethnographies of Ladakh and Tibetan exile communities in India. It notes amchi serving as central community figures, older reciprocal systems of paying amchi that were dismantled by government subsidies between 1989 and 1994, and chapters on how medicines are sourced and compounded.

Mercury in precious pills

Barbara Gerke describes tsotel, a mercury sulfide ash made by processing metallic mercury, as the base of precious pills used for severe disease and as the most refined pharmacological technique in Tibetan medicine. Her university project reports that warnings about toxicity and calls to use precious pills only as prescription drugs appear in brochures but are rarely implemented, and that over-the-counter sales may lead to misuse by uninformed consumers.

An environmental modeling study found elevated mercury in sewage in Tibet and linked it to regular ingestion of mercury-containing Tibetan medicines. It estimated chronic inorganic mercury exposure 34 to 3,000 times higher than from other known dietary sources and that clearing methylmercury from one pill would take about 180 days. The authors concluded the mercury content could be harmful. The study modeled exposure and did not assess patient outcomes.

Animal findings

In rats given tsothel daily for 180 days and then withdrawn for 120 days, kidney mercury remained high after withdrawal. Even so, blood and urine kidney markers and kidney pathology did not differ significantly from controls, and the authors reported reversible stress-related changes. They suggested that formulation method may lower toxicity relative to common mercurials. These are animal results at stated doses and do not show effects in people.

Adverse events and care boundaries

In the Padma 28 trials, mild gastrointestinal discomfort, tiredness and skin eruption were reported, with no difference from placebo (OR 1.09, 95% CI 0.42 to 2.83), though the evidence was rated very low quality. In the 2013 review, 23 studies stated adverse effects; 11 reported none and the others reported rates of 5 to 55 percent. Padma 28 is a herbal formula, and nothing in the opened sources links these data to metal-containing precious pills.

The reviewed evidence does not support delaying or replacing necessary conventional care for conditions such as arterial disease or stroke. This page did not find a verified international training or registration standard for Sowa Rigpa practitioners, and institutions and practitioner roles differ across the countries described.